Mankind Pharma Ltd (MANKIND) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Mankind Pharma completed the acquisition of BSV, expanding into specialty portfolios and R&D platforms.
- Market share in IPM (Indian Pharmaceutical Market) increased by 40 bps to 4.8% in value terms (Dec-2024 vs. Mar-2024), driven by the BSV acquisition.
- INR 13,000 crores raised through NCDs, CPs, and equity for acquisition and debt repayment.
- Corrective measures implemented in the Delhi pharma division to improve field force productivity and efficiency.
- Q3 FY25 revenue increased by 24% YoY to INR 3,230 crores, with a 27.7% adjusted EBITDA margin. Organic growth was 11.2% YoY.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.